Incyte (INCY)

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Company profile

Ticker

INCY

Exchange

NASDAQ

Website

www.incyte.com

CEO

Herve Hoppenot

Incorporated

Delaware

Location

Delaware

Fiscal year end

Dec 31

Sector

Professional, Scientific, and Technical Services > Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Industry (SIC)

Services - Commercial Physical & Biological Research

PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Icon • Medpace • Zymergen • SomaLogic • National Research ...

Former names

INCYTE GENOMICS INC, INCYTE INC, INCYTE PHARMACEUTICALS INC

SEC CIK

0000879169

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Incyte Biosciences Corporation • Incyte Holdings Corporation • Incyte Research Institute LLC • Incyte International Holdings Corporation • Incyte Biosciences Canada Corporation • Incyte International Holdings • Incyte Biosciences International • Incyte Biosciences Austria GmbH • Incyte Biosciences Denmark ApS • Incyte Biosciences Germany GmbH ...

IRS number

943136539

INCY stock data

1M 1Y 5Y

News

From Benzinga Pro

Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock

14 Jun 22

The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate

14 Jun 22

Here's a roundup of top developments in the biotech space over the last 24 hours:

Morning Brief: Top Financial Stories Dominating on Tuesday, June 14

14 Jun 22

CNBC

Lilly-Incyte Snag FDA Nod For Patchy Hair Loss Treatment — Smaller Rival's Stock Shoots Up In Sympathy

14 Jun 22

Pfizer, MorphoSys And Incyte Enter Into Clinical Trial Collaboration For Monjuvi In Combination With TTI-622, A Fusion Protein Directed Against CD47

13 Jun 22

Press releases

From Benzinga Pro

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata

13 Jun 22

INDIANAPOLIS, June 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib), a

Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

13 Jun 22

Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG ((FSE: MOR, NASDAQ:MOR), and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to

Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting

26 May 22

Incyte (NASDAQ:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and

CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)

20 May 22

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19

11 May 22

Analyst ratings and price targets

Last 3 months

Average target

$74.33

Low target

$58.00

High target

$88.00

Calendar

3 May 22

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart INCY financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Incyte earnings reports.

Recent insider trades

INCY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jun 22	Otis W Brawley	Common Stock	Grant	Acquire A	No	No	0	2,144	0	3,399
15 Jun 22	Otis W Brawley	NQSO Common Stock	Grant	Acquire A	No	No	68.55	9,124	625.45K	9,124
15 Jun 22	Fouse Jacqualyn A	Common Stock	Grant	Acquire A	No	No	0	2,144	0	10,655
15 Jun 22	Fouse Jacqualyn A	NQSO Common Stock	Grant	Acquire A	No	No	68.55	9,124	625.45K	9,124
15 Jun 22	Clancy Paul J	Common Stock	Grant	Acquire A	No	No	0	2,144	0	10,434
15 Jun 22	Clancy Paul J	NQSO Common Stock	Grant	Acquire A	No	No	68.55	9,124	625.45K	9,124
15 Jun 22	Harrigan Edmund	Common Stock	Grant	Acquire A	No	No	0	2,144	0	7,716
15 Jun 22	Harrigan Edmund	NQSO Common Stock	Grant	Acquire A	No	No	68.55	9,124	625.45K	9,124
15 Jun 22	Jean Jacques Bienaime	Common Stock	Grant	Acquire A	No	No	0	2,144	0	12,988
15 Jun 22	Jean Jacques Bienaime	NQSO Common Stock	Grant	Acquire A	No	No	68.55	9,124	625.45K	9,124

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

INCY institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	512	517	-1.0%
Opened positions	65	91	-28.6%
Closed positions	70	56	+25.0%
Increased positions	184	196	-6.1%
Reduced positions	187	163	+14.7%

13F shares	Current	Prev Q	Change
Total value	22.78B	21.11B	+7.9%
Total shares	238.32M	236.53M	+0.8%
Total puts	778K	1.29M	-39.7%
Total calls	547.5K	758.64K	-27.8%
Total put/call ratio	1.4	1.7	-16.5%

Largest owners	Shares	Value	Change
Baker Bros. Advisors	36.15M	$2.87B	+7.5%
Baker Julian	34.28M	$4.13B	0.0%
Vanguard	20.89M	$1.66B	-0.3%
BLK Blackrock	18.09M	$1.44B	-1.3%
Dodge & Cox	18.06M	$1.43B	+8.4%
Wellington Management	9.34M	$741.64M	+3.7%
STT State Street	9.25M	$735.01M	-1.0%
RY Royal Bank Of Canada	7.68M	$610.16M	+117.4%
Renaissance Technologies	4.7M	$373.09M	+2.3%
TROW T. Rowe Price	4.69M	$372.66M	-35.5%

Largest transactions	Shares	Bought/sold	Change
RY Royal Bank Of Canada	7.68M	+4.15M	+117.4%
Capital International Investors	1.4M	-2.66M	-65.6%
TROW T. Rowe Price	4.69M	-2.58M	-35.5%
Baker Bros. Advisors	36.15M	+2.54M	+7.5%
UBS UBS Group AG - Registered Shares	2.94M	+1.97M	+204.8%
Norges Bank	0	-1.68M	EXIT
Dodge & Cox	18.06M	+1.4M	+8.4%
Millennium Management	511.35K	-1.27M	-71.4%
Adage Capital Partners GP, L.L.C.	1.59M	+1.1M	+221.7%
Ubs Global Asset Management Americas	2.3M	+966.25K	+72.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Geron • CTI BioPharma • Exelixis • Curis • Infinity Pharmaceuticals • Lumos Pharma • Medicinova • Sierra Oncology • AVEO Pharmaceuticals • AnaptysBio

Management Discussion

We recorded net income of $38.0 million and basic and diluted net income per share of $0.17 for the three months ended March 31, 2022, as compared to net income of $53.5 million and basic and diluted net income per share of $0.24 in the corresponding period in 2021.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: addressing, amplified, boxed, broader, Canadian, Carlo, certificate, chemical, confirmatory, crisaborole, Cyclin, defective, diagnostic, digit, dupilimab, DUPIXENT, eczema, enterprise, EUCRISA, forward, geopolitical, GMP, highlighted, idiopathic, instability, macroeconomic, merit, Monte, Montreal, MZL, neuropathy, NHL, NMPA, occupancy, Pfizer, phototherapy, prednisone, pulmonary, qualification, Regeneron, replication, resource, resourced, retaliatory, roll, Russia, Russian, safer, Sanofi, serine, shift, shrinkage, simulation, SRI, steroid, threonine, Ukraine, visitor, vivo

Removed: absorb, accounted, aged, aging, agnostic, Aid, allocate, allocation, amortizable, amortize, amortized, analyzing, anniversary, Answer, approximate, approximation, assigned, ASU, attribution, attrition, Austrian, axial, bankruptcy, beginning, beneficiary, binary, borrowing, BRAVE, call, Celgene, channel, characteristic, classification, classify, clearance, closely, coincide, collateral, collectability, collected, combined, comparing, conclude, constrain, constrained, constraint, context, controlling, converted, coordinate, counterparty, CRO, custodial, deduct, deducted, depreciation, determinable, dictated, directing, discretion, dispensing, distinct, dividing, dollar, elapsed, eligibility, entirety, environment, examination, expensed, facilitate, feasible, fedratinib, finite, fiscal, fixed, fleet, function, functionality, German, governance, granting, guaranteed, identification, immaterial, inception, inclusion, INREBIC, intangible, Internet, invoiced, judged, judgement, largest, lessee, magnitude, marketability, measuring, mentioned, methodological, methodology, modification, monitored, Motion, mutually, noncurrent, nonrefundable, outset, outsourced, participant, participatory, partnership, payable, payroll, performed, performing, periodically, Pocket, point, predominant, prepaid, prepare, prepay, prepayment, priced, print, printing, professional, progression, protective, prudent, psoriatic, quantitative, radio, realization, recognizing, recoverability, redemption, reliable, relief, renamed, reportable, reputable, residual, Restated, restrictive, retail, reversal, revert, reverting, reviewed, revised, Rodino, rollforward, running, satisfied, sector, secure, setup, shelf, sheltered, shipping, Simplifying, spending, Squibb, standalone, stimulate, subordinated, substantive, taxable, technical, television, thereon, Topic, transferred, transferring, translated, translating, trillion, TrOOP, true, uncured, undiscounted, unpaid, unusual, valid, variable, VIE, voting, waiting, waived, weighting, writing, written

From filing 10-Q 2022 Q1

Financial reports

View all